Real-World, First-Line Osimertinib Treatment in Epidermal Growth Factor Receptor Mutation-Positive (EGFRm) Advanced NSCLC

被引：0
|
作者：
Nieva, J. [1 ]
Griesinger, F. [2 ]
Kim, Y. [3 ]
Cohen, A. [4 ,5 ]
Horvat, P. [6 ]
Lu, S. [7 ]
Taylor, A. [8 ]
Yu, N. [8 ]
Sawyer, W. [8 ]
Shenolikar, R. [8 ]
Shaw, S. [8 ]
机构：
[1] Univ Southern Calif, Norris Canc Ctr, Los Angeles, CA 90007 USA
[2] Pius Hosp Oldenburg, D-26121 Oldenburg, Germany
[3] Kyoto Univ, Grad Sch Med, Kyoto, Japan
[4] Flatiron Hlth Inc, New York, NY 10013 USA
[5] NYU, Sch Med, New York, NY USA
[6] Iqvia, Real World Solut, Emea Data Sci Hub, London, England
[7] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[8] Astrazeneca, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
osimertinib; non-small cell lung cancer; Real-world evidence;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.66
引用
收藏
页码：S616 / S617
页数：2
相关论文
共 50 条
  • [21] COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib
    Sequist, L. V.
    Peled, N.
    Tufman, A.
    Servidio, L.
    Li, J.
    Taylor, R.
    Zhao, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1101 - S1101
  • [22] Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study
    Watanabe, Kageaki
    Yoh, Kiyotaka
    Hosomi, Yukio
    Usui, Kazuhiro
    Naka, Go
    Kishi, Kazuma
    Uemura, Kohei
    Ohashi, Yasuo
    Kunitoh, Hideo
    BMJ OPEN, 2022, 12 (01):
  • [23] A real-world (rw) observational study of long-term survival (LTS) and treatment patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC)
    Nieva, J.
    Karia, P. S.
    Okhuoya, P.
    Berktas, M.
    Salomonsen, R. J-B.
    Servidio, L.
    Chapaneri, J.
    De Silva, K.
    Martin, E.
    Griesinger, F.
    ANNALS OF ONCOLOGY, 2023, 34
  • [24] Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation-positive NSCLC: An interim analysis of the ARIA study
    Wu, L.
    Li, J.
    Xu, C.
    Biswas, B.
    Tang, K.
    Wang, H.
    Liu, Z.
    Batra, U.
    Ho, G. F.
    Low, S. H. J.
    Lu, Y.
    Zhao, M.
    Tho, L. M.
    Zhao, J.
    He, S.
    Huang, J.
    Tang, X.
    Wong, C. H.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34
  • [25] Management of patients with epidermal growth factor receptor mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC) after radiological progression to first-line therapy with gefitinib.
    Hosomi, Yukio
    Tanai, Chiharu
    Yoh, Kiyotaka
    Goto, Yasushi
    Ohashi, Yasuo
    Kunitoh, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Yang, James C-H
    Lee, Chee Khoon
    Kurata, Takayasu
    Kim, Dong-Wan
    John, Thomas
    Nogami, Naoyuki
    Ohe, Yuichiro
    Mann, Helen
    Rukazenkov, Yuri
    Ghiorghiu, Serban
    Stetson, Daniel
    Markovets, Aleksandra
    Barrett, J. Carl
    Thress, Kenneth S.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
  • [27] UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
    Miura, S.
    Maerten, A.
    Popat, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1405 - S1406
  • [28] A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
    Chihara, Yusuke
    Takeda, Takayuki
    Goto, Yasuhiro
    Nakamura, Yoichi
    Tsuchiya-Kawano, Yuko
    Nakao, Akira
    Onoi, Keisuke
    Hibino, Makoto
    Fukuda, Minoru
    Honda, Ryoichi
    Yamada, Takahiro
    Taniguchi, Ryusuke
    Sakamoto, Sinjiro
    Date, Koji
    Nagashima, Seiji
    Tanzawa, Shigeru
    Minato, Koichi
    Nakatani, Koichi
    Izumi, Miiru
    Shimose, Takayuki
    Kishimoto, Junji
    Uchino, Junji
    Takayama, Koichi
    ONCOLOGIST, 2022, 27 (11): : 903 - E834
  • [29] Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
    Fiala, O.
    Pesek, M.
    Finek, J.
    Benesova, L.
    Bortlicek, Z.
    Minarik, M.
    NEOPLASMA, 2013, 60 (04) : 425 - 431
  • [30] Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study
    Lee, J. Y.
    Mai, V.
    Garcia, M.
    Cheng, S.
    Khan, K.
    Balaratnam, K.
    Thakral, A.
    Brown, M. C.
    Zhan, L.
    Corke, L.
    Leighl, N.
    Shepherd, F. A.
    Bradbury, P.
    Sacher, A.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S440 - S440
12345